Prevalence and predictors of peripheral neuropathy after breast cancer treatment

Cancer Medicine

Kalyan Sreeram¹  Michael S. Simon²  Theresa A. Hastert²  Hadeel Assad²  Mark K. Greenwald²  Marian L. Neuhouser³  Mandana Kamgar⁴  Electra D. Paskett⁵  Eric M. McLaughlin⁵  Tracy E. Crane⁶  Jennifer W. Bea⁶  Rami Nassir⁷  Aladdin H. Shadyab⁸  Kerryn W Reding⁹ 

[1] Ascension St Vincent Hospital Indianapolis Indiana USA;Barbara Ann Karmanos Cancer Institute Wayne State University Detroit Michigan USA;Fred Hutchinson Cancer Research Center Seattle Washington USA;Medical College of Wisconsin Milwaukee Wisconsin USA;The Ohio State University Columbus Ohio USA;The University of Arizona Cancer Center Tucson Arizona USA;Umm Al‐Qura’s University Mecca Saudi Arabia;University of California San Diego San Diego, La Jolla California USA;University of Washington Seattle Washington USA;

关键词: breast cancer;    cancer survivors;    chemotherapy;    Peripheral neuropathy;    taxane;   

DOI  :  10.1002/cam4.4202

来源: DOAJ

【 摘 要 】

Abstract Background Many of the 3.8 million breast cancer survivors in the United States experience long‐term side effects of cancer therapy including peripheral neuropathy (PN). We assessed the prevalence and predictors of PN among women with breast cancer followed in the Women's Health Initiative's Life and Longevity After Cancer survivorship cohort. Methods The study population included 2420 women with local (79%) or regional (21%) stage disease. Presence of PN was based on the reports of “nerve problems and/or tingling sensations” after treatment and PN severity was assessed using the Functional Assessment of Cancer Therapy‐Gynecologic Oncology Group/Neurotoxicity instrument. Logistic regression analysis was used to evaluate the socio‐demographic and clinical factors associated with PN prevalence and severity. Results Initial breast cancer treatment included surgery‐only (21%), surgery and radiation (53%), or surgery and chemotherapy (±radiation) (26%). Overall, 17% of women reported PN occurring within days (30%), months (46%), or years (24%) after treatment and 74% reported ongoing symptoms at a median of 6.5 years since diagnosis. PN was reported by a larger proportion of chemotherapy recipients (33%) compared to those who had surgery alone (12%) or surgery+radiation (11%) (p < 0.0001). PN was reported more commonly by women treated with paclitaxel (52%) and docetaxel (39%), versus other chemotherapy (17%) (p < 0.0001). In multivariable analyses, treatment type (chemotherapy vs. none; OR, 95% CI: 3.31, 2.4–4.6), chemotherapy type (taxane vs. no‐taxane; 4.74, 3.1–7.3), and taxane type (paclitaxel vs. docetaxel; 1.59, 1.0–2.5) were associated with higher odds of PN. Conclusion PN is an important long‐term consequence of taxane‐based chemotherapy in breast cancer survivors.

【 授权许可】

Unknown